Clinical trial
Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus…
NCT00056459 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00056459 |
|---|---|
| Title | Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer. |
| Official title | A Randomized, Double-blind, Placebo-controlled, Phase Lll Study in Patients With Metastatic Adenocarcinoma of the Colon or Rectum Who Are Receiving First-line Chemotherapy With Oxaliplatin/5-fluorouracil/Leucovorin With PTK787/ZK 222584 or Placebo |
| Lead sponsor | Novartis, Industry |
| Collaborators | Bayer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms |
| Intervention type | Drug |
| Interventions | Vatalanib |
| Enrollment | 1,168 |
| Start date | Feb 1, 2003 |
| Primary completion | Jan 1, 2007 |
| First posted | Mar 14, 2003 |
| Last update posted | Feb 10, 2020 |
| Countries | Australia, Belgium, Brazil, Canada, Czechia, France, Germany, Hungary, Italy, Netherlands, New Zealand, Portugal and 7 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: